VAERS Explorer
Back to explore

Report #2854864

Received Aug 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
TX
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
HEPHEP B (RECOMBIVAX HB)MERCK & CO. INC.1—OT
HEPHEP B (RECOMBIVAX HB)MERCK & CO. INC.2—OT

Symptoms (2)

Inappropriate schedule of product administrationNo adverse event

Symptom narrative

Child was administered a 2nd dose, too early, 1 week after the first dose.; FBE said there were no adverse side effects reported.; This spontaneous report was received from a nurse and refers to an adolescent patient (also reported as child, discrepancy) of unknown exact age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with the first dose of Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), suspension for injection (dose, route of administration, lot # and expiration date were not reported) as prophylaxis; then, 1 week after the first dose, the patient was vaccinated with the second dose of this vaccine which was too early (dose, route of administration, lot # and expiration date were not reported) as prophylaxis (inappropriate schedule of product administration). No adverse side effects reported (No adverse event). Batch/Lot number is being requested and will be submitted if received.